Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
RYSTIGGO: selected primary-label renal guidance and limits
Product / population
Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.
Renal method
Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
RYSTIGGO: source applicability and renal evidence limits
An explicit no-adjustment instruction and a limited supporting study range can coexist. Preserve both; do not label an unstudied dialysis regimen as clinically validated.
What to reconcile: Subcutaneous infusion only; use the labeled weight-based regimen.
DailyMed / product prescribing information · Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.
Renal method: Population PK: indexed eGFR 38-161 mL/min/1.73 m2 Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Evidence is population PK, not a dedicated severe-renal or dialysis study.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 12.3, Patients with Renal Impairment
The label states no dose adjustment is required with renal impairment. No dedicated renal PK study was performed; population data included mild/moderate impairment, with eGFR 38-161 mL/min/1.73 m2. This explicit instruction is retained without claiming that severe impairment or dialysis was directly validated.
RDM72-rozanolixizumab-rystiggo-label-1 · Source locator: Section 12.3, Patients with Renal Impairment
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
